Clik here to view.
苏爱康与日本化药宣布签署候选新药DARINAPARSIN (SP-02)的日本市场许可协议
东京 (美国商业资讯)–苏爱康制药有限公司（Solasia Pharma K.K，TOKYO: 4597；总部：日本东京；总裁兼首席执行官：Yoshihiro Arai.，以下简称“苏爱康”）和日本化药株式会社（Nippon Kayaku Co., Ltd；TOKYO: 4272；总部：日本东京；总裁：Atsuhiro...
View ArticleClik here to view.
武田将收购GammaDelta Therapeutics，以加速开发针对实体瘤的异体γδT细胞疗法
日本大阪和伦敦 (美国商业资讯)–武田药品工业株式会社（Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK，简称“武田”）今天宣布行使其收购GammaDelta Therapeutics Limited (“GammaDelta”)的选择权。GammaDelta...
View ArticleClik here to view.
Vernalis Research – a Fully Owned Subsidiary of HitGen Inc – and Hannibal...
CHENGDU, China Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Hannibal Innovation ApS (“Hannibal”) are pleased to announce the creation of Dania Therapeutics ApS...
View ArticleClik here to view.
Clik here to view.
Imugene and Eureka Therapeutics Announce Strategic Collaboration to...
SYDNEY & EMERYVILLE, Calif. Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company, and Eureka Therapeutics, Inc. (“Eureka”), a clinical-stage biotechnology company...
View ArticleClik here to view.
武田创造强劲的2021财年上半年业绩；受14个全球品牌的推动，增长态势有望进一步持续到财年年底
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited) (TOKYO:4502/NYSE:TAK)（简称“武田”）今天公布了2021财年上半年（截至2021年9月30日）财务业绩。基于上半年强劲的业绩，公司还确认了其2021财年管理层指引。...
View ArticleClik here to view.
ZAP Surgical 任命 业 内 资 深人士 领导 中国市 场 的拓展工作
加利福尼亚州圣卡洛斯市 (美国商业资讯)–ZAP-X®陀螺放射外科(Gyroscopic Radiosurgery®)平台的制造商ZAP Surgical Systems, Inc.今天宣布任命Jie Sun博士为副总裁， 负责大中华区，任命Calvin...
View ArticleClik here to view.
ZAP Surgical Appoints Industry Veterans to Lead Chinese Market Expansion
SAN CARLOS, Calif. ZAP Surgical Systems, Inc., maker of the ZAP-X® Gyroscopic Radiosurgery® platform, today announced the appointment of Jie Sun, PhD, as Vice President, Greater China, and Calvin...
View ArticleClik here to view.
Rhizen Pharmaceuticals AG宣布，在一项有关使用其新型PARP抑制剂(RP12146)治疗晚期实体瘤的I/Ib期研究中进行了首例患者给药
瑞士巴塞尔 –(美国商业资讯)–总部位于瑞士并致力于肿瘤和炎症药物开发的临床阶段私营生物制药公司Rhizen Pharmaceuticals AG...
View ArticleClik here to view.
Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical...
SOUTH SAN FRANCISCO, Calif. Veracyte, Inc. (Nasdaq: VCYT) today announced that its Immunoscore Colon Cancer test has been included in the Pan-Asian adapted ESMO1 Clinical Practice Guidelines for the...
View ArticleClik here to view.
Exscientia to Report Third Quarter 2021 Financial Results on November 17, 2021
OXFORD, England Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, will...
View ArticleClik here to view.
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of...
FOSTER CITY, Calif., & SHANGHAI Gilead Sciences, Inc. (Nasdaq: GILD) today reported that the Everest Medicines (HKEX 1952.HK) sponsored Phase 2b EVER-132-001 study of sacituzumab govitecan...
View ArticleClik here to view.
Cyclica and the Structural Genomics Consortium Co-crystallize DCAF1, a Key...
TORONTO Cyclica, the partner of choice for data-driven drug discovery, and the Structural Genomics Consortium (SGC), a global public-private partnership dedicated to open science, have collaborated...
View ArticleClik here to view.
Clik here to view.
Clik here to view.
U.S. FDA Approves BESREMi® (ropeginterferon alfa-2b-njft) as the Only...
BURLINGTON, Mass. PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in...
View ArticleClik here to view.
Clik here to view.
为女性创建更美好世界25周年：玫琳凯艾施基金会庆祝重大纪念日
达拉斯 — (美国商业资讯)–为庆祝基金会成立25周年，在玫琳凯·艾施(Mary Kay Ash)丰富全球女性生活这一梦想的指引下，玫琳凯艾施基金会(Mary Kay Ash...
View ArticleClik here to view.
Clik here to view.
Icure Acquires Drug Product Approval for World’s First Donepezil Patch for...
SEOUL, South Korea Icure Pharmaceutical Inc. (KOSDAQ: 175250), a biopharmaceutical company in Korea, announced today that its donepezil patch, a treatment of Alzheimer’s-type dementia, received a...
View Article